Screening for drugs to reduce zebrafish aggression identifies caffeine and sildenafil
dc.contributor.author | Gutiérrez, HC | |
dc.contributor.author | Vacca, I | |
dc.contributor.author | Schoenmacker, G | |
dc.contributor.author | Cleal, M | |
dc.contributor.author | Tochwin, A | |
dc.contributor.author | O'Connor, B | |
dc.contributor.author | Young, AMJ | |
dc.contributor.author | Vasquez, AA | |
dc.contributor.author | Winter, MJ | |
dc.contributor.author | Parker, MO | |
dc.contributor.author | Norton, WHJ | |
dc.date.accessioned | 2019-11-26T14:05:53Z | |
dc.date.issued | 2019-11-01 | |
dc.description.abstract | Although aggression is a common symptom of psychiatric disorders the drugs available to treat it are non-specific and can have unwanted side effects. In this study we have used a behavioural platform in a phenotypic screen to identify drugs that can reduce zebrafish aggression without affecting locomotion. In a three tier screen of ninety-four drugs we discovered that caffeine and sildenafil can selectively reduce aggression. Caffeine also decreased attention and increased impulsivity in the 5-choice serial reaction time task whereas sildenafil showed the opposite effect. Imaging studies revealed that both caffeine and sildenafil are active in the zebrafish brain, with prominent activation of the thalamus and cerebellum evident. They also interact with 5-HT neurotransmitter signalling. In summary, we have demonstrated that juvenile zebrafish are a suitable model to screen for novel drugs to reduce aggression, with the potential to uncover the neural circuits and signalling pathways that mediate such behavioural effects. | en_GB |
dc.description.sponsorship | European Union FP7 | en_GB |
dc.description.sponsorship | NC3Rs | en_GB |
dc.identifier.citation | Published online 1 November 2019 | en_GB |
dc.identifier.doi | 10.1016/j.euroneuro.2019.10.005 | |
dc.identifier.grantnumber | 602805 | en_GB |
dc.identifier.grantnumber | NC/R001049/1 | en_GB |
dc.identifier.uri | http://hdl.handle.net/10871/39811 | |
dc.language.iso | en | en_GB |
dc.publisher | Elsevier for European College of Neuropsychopharmacology | en_GB |
dc.rights | © 2019 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license. (https://creativecommons.org/licenses/by-nc-nd/4.0) | en_GB |
dc.subject | Zebrafish | en_GB |
dc.subject | Aggression | en_GB |
dc.subject | Drug screen | en_GB |
dc.subject | Behaviour | en_GB |
dc.subject | Caffeine | en_GB |
dc.subject | Sildenafil | en_GB |
dc.title | Screening for drugs to reduce zebrafish aggression identifies caffeine and sildenafil | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2019-11-26T14:05:53Z | |
dc.identifier.issn | 0924-977X | |
dc.description | This is the final version. Available on open access from Elsevier via the DOI in this record | en_GB |
dc.identifier.journal | European Neuropsychopharmacology | en_GB |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | en_GB |
dcterms.dateAccepted | 2019-10-10 | |
rioxxterms.version | VoR | en_GB |
rioxxterms.licenseref.startdate | 2019-11-01 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2019-11-26T14:02:49Z | |
refterms.versionFCD | VoR | |
refterms.dateFOA | 2019-11-26T14:05:56Z | |
refterms.panel | A | en_GB |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's licence is described as © 2019 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license.
(https://creativecommons.org/licenses/by-nc-nd/4.0)